Загрузка...
Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
INTRODUCTION: In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT; ClinicalTrials.gov number NCT01994889), tafamidis reduced the risk of all-cause mortality in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) by 30% versus placebo. Median overall survival was not ac...
Сохранить в:
| Опубликовано в: : | Cardiol Ther |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer Healthcare
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7584686/ https://ncbi.nlm.nih.gov/pubmed/32524297 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40119-020-00179-2 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|